Friday, August 8, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Medicine

A blood test for stroke risk? Study finds network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease

May 1, 2024
in Medicine
Reading Time: 4 mins read
0
A blood test for stroke risk? Study finds network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease
67
SHARES
607
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT
ADVERTISEMENT

A simple blood test could allow doctors to determine whether a person may be at higher risk for stroke or cognitive decline during their lifetime, according to a new UCLA Health study. 

A simple blood test could allow doctors to determine whether a person may be at higher risk for stroke or cognitive decline during their lifetime, according to a new UCLA Health study. 

The study, published in the journal Stroke, found that measuring concentrations of a network of inflammatory molecules in the blood could allow doctors to calculate a risk score for susceptibility for cerebral small vessel disease – a common cause of stroke and a contributor to cognitive decline found especially among the elderly.  

Currently, the only way to determine a person’s risk for cerebral vascular diseases has been to use a combination of imaging such as an MRI scan, family history, demographic variables and other risk factor evaluations, said study lead author Dr. Jason Hinman of the UCLA Comprehensive Stroke and Center and the Mary S. Easton Center for Alzheimer’s Research and Care at UCLA. In clinical practice, neurologists may only find a patient is at risk after they have had a stroke or a cerebral event that warns of one, Hinman said. 

The new study found that by measuring the concentrations of this network of inflammatory molecules in the blood of patients who have not had a cerebrovascular event, medical providers may be able to quantitatively assess a person’s risk for cerebral small vessel disease and future stroke. 

“The same way one uses cholesterol tests to evaluate one’s future risk for heart attack, we don’t have such a thing to estimate future risk for stroke,” Hinman said. “I believe we can do that by something as simple as a blood test which in theory can enable broader access to the best level of care and not lock it behind advanced imaging studies and specialist evaluations.” 

The study focused on a biologically-connected network of inflammatory molecules known as the interleukin-18, or IL-18, network, which includes proteins and signaling molecules used to fight various infections.  

Past studies have linked individual molecules in the IL-18 network to cerebral small vessel disease and stroke risk. However, the concentration of these individual molecules can fluctuate in response to other ailments such as the flu or autoimmune disorders, making them unreliable predictors of stroke risk at an individual level, Hinman said. 

In 2020, University of California researchers including Hinman found that six molecules in the IL-18 network were associated with the presence of vascular brain injuries during MRI scans.  

Building off these findings, Hinman sought to determine in this latest publication whether IL-18 network could be used to assess a person’s susceptibility to stroke risk or cognitive decline.  

To test this, the researchers used health data from a generations-long study known as the Framingham Heart Study. This study has tracked the medical history of thousands of residents in the city of Framingham, Massachusetts, throughout their lives since launching in 1948. Blood samples taken from participants had been tested for five of the six molecules later identified as being in the IL-18 network. 

By using the blood samples and medical histories of the Framingham participants, Hinman and his coauthor were able to create a mathematical model that generates a risk score based on the concentrations of the IL-18 network molecules. Of the more than 2,200 Framingham residents included in Hinman’s study, those whose risk scores were in the top 25% had an 84% chance of having a stroke during their lifetime. Overall, elevated risk scores were associated with a 51% increased risk of stroke and resulted in diagnostic prediction compared to existing risk assessment tools. 

What remains unclear and requires further study is how or if a person’s risk score can be modified or reduced, Hinman said. 

“The real challenge is in the primary care space. Are you at risk before you have an event?” Hinman said. “That’s what we’re all interested in doing is preventing a stroke before it even happens.” 

Article: Association of Incident Stroke Risk with an IL-18-centered Inflammatory Network Biomarker Composite Published May 1, 2024, Martirosian et al., Stroke, https://doi.org/10.1161/STROKEAHA.123.044719 



Journal

Stroke

DOI

10.1161/STROKEAHA.123.044719

Method of Research

Data/statistical analysis

Subject of Research

People

Article Title

Association of Incident Stroke Risk with an IL-18-centered Inflammatory Network Biomarker Composite

Article Publication Date

1-May-2024

COI Statement

Cristina Teran: Ms. Teran is a former UCLA Health employee supported by NIH funding.
David S. Liebeskind: Dr. Liebeskind is scientific advisor and on the Board of Directors of Sage Cerebrovascular Diagnostics, Inc.
Emer R. McGrath: Dr. McGrath receives grant support from the Health Research Board.
Charlie DeCarli: Dr. DeCarli is a consultant to Eisai and Novo Nordisk.
Jayandra J. Himali: Dr. Himali receives grant support from NIH, the Alzheimer’s Drug Discovery Foundation, and the Alzheimer’s Association.
Sudha Seshadri: Dr. Seshadri is a consultant for Biogen and Eisai.
Jason D. Hinman: Dr. Hinman is a listed inventor on the following patents held by the Regents of the University of California that include blood measurement of the molecules included in this study: Japan Patent No. 7211626; Korea Patent No. 10-2538752; US Application 62/461,161; Canada Application #3,054,083; EPO Application #18755090.0. Dr. Hinman is also the founder of Sage Cerebrovascular Diagnostics, Inc. which has an exclusive license from the Regents to commercialize diagnostic tests using these markers.

Share27Tweet17
Previous Post

Brief anger may impair blood vessel function

Next Post

New survey finds 75% of Americans feel mental health takes back seat to physical health within U.S. healthcare system

Related Posts

blank
Medicine

New Phase II Trial Targets Advanced Follicular Lymphoma

August 8, 2025
blank
Medicine

Scientists Develop “Evolution Engine” to Accelerate Protein Reprogramming

August 8, 2025
blank
Medicine

Autoantibodies Trigger Sensory Neuron Pain in Rats

August 7, 2025
blank
Medicine

New Clue: Odorant Protein Fibrils Cause Smell Loss

August 7, 2025
blank
Medicine

Toe Transfer Surgery Shows Promise in Enhancing Recovery After Finger Amputation

August 7, 2025
blank
Medicine

Rapid Extraction-Free HPV DNA Test in Mozambique

August 7, 2025
Next Post
Cost Is Top Barrier for American in Seeking Mental Health Treatment

New survey finds 75% of Americans feel mental health takes back seat to physical health within U.S. healthcare system

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27531 shares
    Share 11009 Tweet 6881
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    942 shares
    Share 377 Tweet 236
  • Bee body mass, pathogens and local climate influence heat tolerance

    641 shares
    Share 256 Tweet 160
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    506 shares
    Share 202 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    310 shares
    Share 124 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Two Key Barriers Women Face: Ambivalent Sexism
  • New Phase II Trial Targets Advanced Follicular Lymphoma
  • Eco-Friendly ZIF-7 Carbon for Sensitive Rhodamine B Detection
  • Deep Learning Model Enhances Detecting Brain Hemorrhage

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,858 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading